INTRODUCTION 74
There is longstanding interest in the concept of immune surveillance of cancer. For 75 example, in murine models, several lines of evidence indicate that the immune system can 76 recognize nascent tumors and prevent their outgrowth (1) . In a chemical carcinogenesis model, 77
host T cells were shown to prevent tumor development through recognition of a single somatic 78 point mutation in the spectrin-beta2 gene (2). However, equivalent evidence of primary immune 79 surveillance in humans is lacking, apart from T cell-mediated control of virus-induced cancers 80 (3). More obvious in humans is the influence of the immune system on cancer progression and 81 clinical outcomes. In particular, the presence of CD8+ tumor-infiltrating lymphocytes (TIL) is 82 strongly associated with favorable prognosis in virtually every solid human cancer studied (4). 83
Other TIL subsets, including CD20+ B cells, further contribute to this effect (5-7). Thus, the 84 immune system can mount seemingly protective anti-tumor responses in many cancer patients. 85
In addition to spontaneous immune responses, there is increasing evidence that tumor 86 immunity is enhanced by certain cancer treatments, including hormone, radiation and 87 chemotherapy (8). This is thought to occur by the process of immunogenic cell death, in which 88 dying tumor cells release tumor-specific antigens and danger-associated molecules such as 89 calreticulin, HMGB1 and ATP, leading to enhanced presentation of tumor antigens to the 90 immune system (8). For example, we recently showed in estrogen receptor-negative breast 91 cancer that patients with pre-existing CD8+ TIL show survival benefit from anthracycline-based 92 chemotherapy, whereas patients lacking CD8+ TIL do not (9); this suggests that anthracyclines Immunohistochemistry was performed using a Ventana Discovery XT autostainer 156 (Ventana, Tucson, AZ) with primary antibodies to CD3 (Clone SP7, Spring Biosciences, 157 catalogue #M3074), CD8 (Clone SP16, Spring Biosciences, catalogue #M3162), CD4 (Clone 158 SP35, Spring Biosciences catalogue #M3354), CD20 (Spring Biosciences catalogue #E2560), 159 MHC class I (clone EMR8-5, MBL catalogue #D226-3, Woburn, MA), and MHC class II (clone 160 CR3/43, Affinity Bioreagents catalogue # MAI-25914). Bound antibodies were detected using a 161 biotinylated secondary antibody (Jackson Immunoresearch, West Grove, PA) and a DABMap kit 162 (Ventana) followed by counterstaining with hematoxylin (Ventana). Lymphocyte densities and 163 MHC intensity were scored by visual inspection using semi-quantitative scales described in 164 
In vitro T cell line generation 169
Bulk ascites or tumor cells were thawed and incubated in complete media in 6-well plates 170 at a concentration of 1x10 6 cells ml in the presence of either high dose human IL-2 (6000 IU/ml, 171 (National Cancer Institute) or anti-CD3/anti-CD28 coated beads (Dynabeads Human T-Activator 172 CD3/CD28, Life Technologies) plus low dose IL-2 (300 IU/ml). For CD8-enriched lines, bulk 173 ascites cells were labeled with PE-conjugated anti-human CD8 antibody (BD Biosciences), and 174 magnetic separation was performed using anti-PE MicroBeads (Miltenyi Biotec). CD8+ T cells 175 were expanded in vitro using the rapid expansion protocol (REP) (32). Cultures were split every 176 3-4 days with addition of fresh cytokines, and additional REPs were performed as needed. Prior 177 to ELISPOT, cells were cultured in resting media consisting of complete media containing 10 178 ng/ml IL-7 (Peprotech) and 1 IU/ml IL-2 for 3 days. 179
180

T cell cloning 181
An HSDL1-specific CD8+ T cell clone (Clone 1) was generated by limiting dilution 182 cloning. In brief, CD8+ T cells from an IL-2 expanded cell line exhibiting HSDL1 
Screening for T cell responses to tumor mutations 273
We investigated whether the three patients had spontaneous T cell responses to the 274 mutations identified by whole exome sequencing. Given that the mutational profiles were 275 derived from ascites tumor samples, we assessed tumor-associated lymphocyte (TAL) lines 276 derived from matched ascites samples. In initial experiments, TAL were expanded using a well-277 established method involving high dose IL-2 (32). TAL lines were tested by IFN-γ ELISPOT for 278 recognition of (a) predicted minimal peptides (Supplemental Tables 1-3) (39). We tested all identified non-synonymous mutations except those that were present in 283 germline (e.g., BRCA1), or resulted in non-translated genes (e.g. SPATS2 concern that mutation-specific T cells might have been lost during IL-2 expansion, we generated 293 additional T cell lines from ascites samples using an alternate expansion method involving anti-294 CD3/anti-CD28 coated beads. In addition, we tested TAL directly ex vivo in bulk ascites samples. 295
As before, we failed to detect T cell responses to any of the mutant peptides, whereas T cell 296 responses were seen to the CEF peptides and anti-CD3/anti-CD28 coated beads (data not shown). 297
In contrast to the first two patients, TAL lines from Patient 3 showed a clear response to 298 predicted minimal and 15-mer peptides corresponding to a point mutation in the hydroxysteroid 299 dehydrogenase-like protein 1 gene (HSDL1 L25V ) (Fig. 2 ). This T cell response was detected in 300 TAL lines generated with high dose IL-2 ( 
CYMEAVAL in the context of HLA-C*14:03 (Supplemental Fig. 4 ). This interaction was also 319 predicted by the NetMHCpan-2.4 algorithm in that CYMEAVAL had the strongest predicted 320 HLA binding score of all candidate epitopes encoding HSDL1 L25V across all 6 HLA alleles for 321 this patient (Supplemental Table 3 ). Notably, Clone 1 demonstrated absolute specificity for 322 mutated HSDL1 when assessed using either minimal peptides or 15-mer peptides comprising the 323 wild type HSDL1 sequence (Fig. 3) . but not the primary sample or second recurrence (Fig. 4D) . The PCR assay further revealed that 365 system. Yet responses to such mutations might still be thwarted by factors such as peripheral 417 tolerance or immune suppression (41). Another possibility is immunological ignorance, in which 418 a potentially visible mutation fails to elicit a T cell response due to ineffective priming, 419 competition from higher affinity peptides, physical barriers or other mechanisms (42, 43). We do 420 not know how many of the mutations studied here were subject to immunological ignorance, as 421 our stimulation methods were not designed to prime naïve T cell responses. However, such 422 mutations are worthy of further study, as they represent an attractive class of potential target 423 antigens for immunotherapy (44). 424
Although our sample size was small, we considered several possible reasons why Patient 425 3 mounted a mutation-specific T cell response whereas the other two patients did not. First, 426
Patient 3 had more mutations than the other patients, which increases the mathematical 427 probability of having an immunogenic mutation. Second, Patient 3 showed the greatest number 428 of changes in the mutanome over time (11 versus 1-6 changes). Indeed, the prevalence of the 429 HSDL1 L25V mutation increased from 3.5% to 60% of tumor cells during progression from 430 primary to recurrent disease; the corresponding rise in the abundance of the mutant epitope might 431 have been sufficient to break immunological ignorance or tolerance. Third, Patient 3 experienced 432 the greatest decrease in tumor burden during chemotherapy (Fig. 1) (31 
